Back to search results

Smartphone App for Opioid Use Disorder Relapse Prevention

This study is testing a smartphone app called OptiMAT to help prevent relapse in people receiving medication-assisted treatment (MAT) for opioid use disorder. The app helps you track your drug use daily and gives you personalized feedback. It also uses location tracking to offer support when you enter areas you've identified as high-risk for relapse. We are looking for people aged 18 and older who are in the early stages of MAT. The main goal is to see if OptiMAT can reduce opioid use over six months, measured by urine tests. A smaller group will also have brain scans (fMRI) to understand how the brain responds to treatment. The study aims to enroll 336 participants, but its current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 336 participants. Participants will be randomly assigned to either use the OptiMAT app or a monitoring-only group.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Opioid use will be measured through urinalysis at Week 0 (Intake), Week 1, and Week 2.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05336188

Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder

Enrolling by Invitation
NAAges 18+InterventionalTreatment
University of Arkansas
~336 participants
Updated 2026-05-15 on ClinicalTrials.gov
What's tested:Smartphone

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Urinalysis - Week 0 (Intake)
Measured over 1 day
+26 more outcomes measured

Conditions

Opioid-Related Disorders
Mobile Applications
Opiate Substitution Treatment
Magnetic Resonance Imaging
Craving
Attentional Bias
Ecological Momentary Assessment

Explore related trials

Opioid Use Disorder

Where it's being run

1 sites across 1 states
Arkansas1

Study leadership

  • Andrew James, Ph.D. · PRINCIPAL_INVESTIGATOR · University of Arkansas

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Sex: male or female
Age: 18 years and older
(MRI sub-study): Age: 18-50 years old
In Phase I treatment of MAT for opioid-use disorder. (Phase I indicates that patient is receiving no more than one week of take-home medications at each weekly clinic visit.)
Must be willing to use a smartphone if randomized to the smartphone intervention arm
(MRI sub-study): Native English-speaking

Exclusion

(MRI) Medical history: A history of neurological, cardiovascular, or infectious disease would exclude study participation. A loss of consciousness of 20 or more min or other evidence of brain trauma also would be exclusionary.
(MRI) Pregnancy: A positive test for pregnancy prior to fMRI would exclude participation, due to unknown effect of high-field MRI on developing fetus.

What this trial measures

  • Urinalysis - Week 0 (Intake)1 day

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 11 week

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 22 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 33 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 44 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 55 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 66 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 77 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 88 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 99 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 1010 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 1111 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 1212 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 1313 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 1414 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 1515 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 1616 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 1717 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 1818 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 1919 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 2020 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 2121 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 2222 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 2323 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 2424 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 2525 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone

  • Urinalysis - Week 2626 weeks

    Percent of weekly urinalysis tests positive for opioid metabolite other than Suboxone